Hematology/Oncology · Canton, OH
NPI
1104854751
Since 2006
Specialty
Hematology/Oncology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
4875 Higbee Ave NW
Canton, OH, 44718
Phone (330) 492-3345
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
97,060 services
Medicare patients, 2024
147
Average age 72
Drug cost, 2024
$4.7M
1,711 prescriptions
Company payments, 2025
$17K
From 55 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nashat Gabrail was code J2350 (injection, ocrelizumab, 1 mg), 8,400 times for 12 patients. In total Nashat Gabrail billed 97,060 services in 147 codes, and Medicare paid $1.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-04-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2350 Injection, ocrelizumab, 1 mg | Office | 8,400 | 12 | $43.88 | $369K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 5,750 | 35 | $0.10 | $603 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,720 | 19 | $0.09 | $155 |
| 85025 Blood Count | Office | 536 | 105 | $7.58 | $4,064 |
| 36415 Venipuncture Blood Collection | Office | 461 | 102 | $7.82 | $3,606 |
| 96367 Intravenous Infusion, Hydration | Office | 430 | 43 | $20.07 | $8,628 |
| 83735 Clinical Chemistry | Office | 413 | 102 | $6.51 | $2,689 |
| 84100 Clinical Chemistry | Office | 413 | 102 | $4.61 | $1,903 |
| 80053 Clinical Chemistry | Office | 411 | 102 | $10.26 | $4,215 |
| 84550 Clinical Chemistry | Office | 410 | 102 | $4.39 | $1,800 |
| 83615 Clinical Chemistry | Office | 405 | 101 | $5.87 | $2,376 |
| 82575 Clinical Chemistry | Office | 402 | 102 | $9.18 | $3,692 |
| J3480 Injection, potassium chloride, per 2 meq | Office | 390 | 14 | $0.09 | $33.15 |
| 96375 Injection Administration | Office | 276 | 45 | $11.01 | $3,039 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 251 | 61 | $0.63 | $157 |
By year: 2022 $1.9M for 95,987 services; 2023 $1.8M for 92,226 services; 2024 $1.3M for 97,060 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 536 | 105 | $7.58 | $4,064 |
| 36415 Venipuncture Blood Collection | 461 | 102 | $7.82 | $3,606 |
| 83735 Clinical Chemistry | 413 | 102 | $6.51 | $2,689 |
| 84100 Clinical Chemistry | 413 | 102 | $4.61 | $1,903 |
| 80053 Clinical Chemistry | 411 | 102 | $10.26 | $4,215 |
| 84550 Clinical Chemistry | 410 | 102 | $4.39 | $1,800 |
| 83615 Clinical Chemistry | 405 | 101 | $5.87 | $2,376 |
| 82575 Clinical Chemistry | 402 | 102 | $9.18 | $3,692 |
| 83550 Clinical Chemistry | 59 | 31 | $8.57 | $506 |
| 83540 Clinical Chemistry | 59 | 31 | $6.24 | $368 |
Medicare prescription drug claims, 2024
In 2024, the drug Nashat Gabrail prescribed most often to Medicare patients was Procrit (Epoetin Alfa), with 133 prescriptions and refills. In total Nashat Gabrail wrote 1,711 Medicare prescriptions that cost $4.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Procrit Epoetin Alfa | 133 | 133 | 19 | $132K |
| Zarxio Filgrastim-Sndz | 121 | 121 | 13 | $106K |
| Xarelto Rivaroxaban | 80 | 110 | 15 | $55K |
| Bortezomib Generic | 60 | 60 | Under 11 | $8,686 |
| Ibrance Palbociclib | 55 | 55 | Under 11 | $859K |
| Metoclopramide Hcl Generic | 48 | 48 | 33 | $241 |
| Dexamethasone Generic | 48 | 55 | 17 | $837 |
| Imatinib Mesylate Generic | 46 | 46 | Under 11 | $6,431 |
| Megestrol Acetate Generic | 44 | 46 | 20 | $1,644 |
| Lupron Depot Leuprolide Acetate | 36 | 36 | Under 11 | $72K |
| Warfarin Sodium Generic | 34 | 70 | 11 | $247 |
| Diltiazem 24hr Er (Cd) Diltiazem Hcl | 31 | 56 | Under 11 | $921 |
| Allopurinol Generic | 31 | 58 | 14 | $130 |
| Exemestane Generic | 31 | 34 | Under 11 | $2,444 |
| Prednisone Generic | 30 | 30 | 14 | $111 |
Brand drugs: - claims; generic drugs: 988 claims; opioid claims: 102.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nashat Gabrail $17K ($4,450 in general payments such as food, travel and fees and $13K for research) from 55 companies. The largest payer was Acrotech Biopharma Inc. with $11K.
| Company | Payments | Amount |
|---|---|---|
| Acrotech Biopharma Inc. | 3 | $11K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 21 | $2,045 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 5 | $1,676 |
| Sanofi US Services Inc. SNY | 1 | $1,247 |
| Exelixis Inc. EXEL | 2 | $123 |
| Genzyme Corporation SNY | 1 | $110 |
| Sobi, Inc SOBI.ST | 3 | $103 |
| Invivyd Inc IVVD | 3 | $82.7 |
| Avyxa Pharma, LLC | 1 | $79.17 |
| Shorla Oncology Inc. | 2 | $64.26 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.